Back

Inhibiting LSD1 suppresses coronavirus-induced inflammation but spares innate antiviral activity

Mazzarella, L.; Santoro, F.; Ravasio, R.; Massa, P.; Rodighiero, S.; Gaviln, E.; Romanenghi, M.; Duso, B.; Bonetti, E.; Pallavi, R.; Trastulli, D.; Pallavicini, I.; Gentile, C.; Leonardi, T.; Buttinelli, G.; Pasqualato, S.; Di Martino, A.; Fedele, G.; Schiavoni, I.; Stefanelli, P.; Meroni, G.; Steinkuhler, C.; Fossati, G.; Minucci, S.; Pelicci, P. G.

2021-05-03 immunology
10.1101/2021.05.02.441948 bioRxiv
Show abstract

Tissue-resident macrophages exert critical but conflicting effects on the progression of coronavirus infections by secreting both anti-viral type I Interferons and tissue-damaging inflammatory cytokines. Steroids, the only class of host-targeting drugs approved for Covid19, indiscriminately suppress both responses, possibly impairing viral clearance, and provide limited clinical benefit. Here we set up a mouse in vitro co-culture system that reproduces the macrophage response to SARS-CoV2 seen in patients and allows quantitation of inflammatory and antiviral activities. We show that the NFKB-dependent inflammatory response can be selectively inhibited by ablating the lysine-demethylase LSD1, which additionally unleashed interferon-independent ISG activation and blocked viral egress through the lysosomal pathway. These results provide a rationale for repurposing LSD1 inhibitors, a class of drugs extensively studied in oncology, for Covid-19 treatment. One-Sentence SummaryTargeting a chromatin-modifying enzyme in coronavirus infections curbs tissue-damage without affecting antiviral response

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.